Eriocalyxin B Induces Apoptosis in Lymphoma Cells Through Multiple Cellular Signaling Pathways

Yi-Wen Zhang,Xiao-Xing Jiang,Qiu-Sheng Chen,Wen-Yu Shi,Lan Wang,Han-Dong Sun,Zhi-Xiang Shen,Zhu Chen,Sai-Juan Chen,Wei-Li Zhao
DOI: https://doi.org/10.1016/j.exphem.2009.12.005
IF: 3.249
2010-01-01
Experimental Hematology
Abstract:Objective. Eriocalyxin B (EriB) is a natural diterpenoid purified from Isodon eriocalyx var. laxiflora and possesses strong antileukemic activity. In this study, we further investigated its effect and mechanism of action in human lymphoma.Materials and Methods. In vitro, a series of B- and T-lymphoma cells were treated with EriB. Cell apoptosis was analyzed using flow cytometric assay. Expression of proteins related to apoptosis and cell signal transduction were assessed using Western blot. In vivo antitumor activity of EriB was examined in marine xenograft B- and T-lymphoma models, with in situ cell apoptosis detected by terminal deoxytransferase-catalyzed DNA nick-end labeling assay.Results. EriB significantly inhibited lymphoma cell proliferation and induced apoptosis in association with caspase activation. Antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL were downregulated, with proapoptotic member Bax stable or upregulated, resulting in reduced Bcl-2/Bax and Bcl-xL/Bax ratios. Meanwhile, multiple signal transduction pathways were involved in lymphoma cell apoptosis in response to EriB, including inhibition of nuclear factor (NF)-kappa B and AKT pathways, and the activation of extracellular signal-related kinase (ERK) pathway. AKT inactivation was related to increased expression of cyclin-dependent kinase inhibitor P21, decreased expression of antiapoptotic phosphorylated form of Bad, and NF-kappa B activator 1 kappa B kinase alpha/beta. ERK activation corresponded to reactive oxygen species production and could be blocked by antioxidant dithiothreitol. In murine xenograft lymphoma models. krill remarkably inhibited tumor growth and induced in situ tumor cell apoptosis.Conclusion. These findings broaden the value of EriB as a promising candidate targeting apoptosis cascade in treatment of hematological malignancies. (C) 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
What problem does this paper attempt to address?